Trial Profile
A phase IV, single group study to evaluate the immunogenicity and safety in UK laboratory workers of a licensed Hib and meningococcal C conjugate combined vaccine (Menitorix)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2019
Price :
$35
*
At a glance
- Drugs Hib-meningococcal vaccine group C conjugate (Primary)
- Indications Haemophilus infections; Meningococcal group C infections
- Focus Pharmacodynamics
- 19 Sep 2007 Status change from in progress to completed
- 16 Aug 2007 New trial record.